Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development. (November 2014)

• Record Type: Journal Article
• Authors: Parikh, Sameer A; Litzow, Mark R
• Is Part Of: Future oncology. Volume 10:Number 14(2014)
• Page Start: 2201
• Page End: 2212
• Publication Date: 2014-11
• Subjects: chimeric antigen receptor therapy -- immunotoxin -- NOTCH1 inhibitors -- novel monoclonal antibodies -- proteasome inhibitors; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.81
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : Although the prognosis of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) has steadily improved over the past decade, less than 50% of patients maintain their remission at 5 years. Several approaches have been explored in the past few years including: monoclonal antibodies – either 'naked' (rituximab) or in combination with an immunotoxin (calicheamicin or maytansin), plant toxin (ricin), or bacterial toxin ( Pseudomonas or diphtheria), and a novel bispecific T-cell-engaging antibody (blinatumomab); chimeric antigen therapy using autologous T cells that target CD19-expressing ALL; and novel agents such as proteasome inhibitors, liposomal vincristine, hypomethylating agents, nelarabine and NOTCH1 inhibitors. This review summarizes treatment approaches currently under investigation for the treatment of adult Philadelphia chromosome-negative ALL.